|
|
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness |
| 1K02DA054304-01A1 |
|
NIDA |
2022 |
|
|
Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic |
| 1R01DA055131-01 |
|
NIDA |
2022 |
|
|
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability |
| 1R01DA057568-01 |
|
NIDA |
2022 |
|
|
Neurocognitive implications of cannabidiol (CBD) while aging with HIV |
| 1R03DA057146-01 |
|
NIDA |
2022 |
|
|
Social determinants of substance use disorder treatment outcomes in a vulnerable population |
| 1R21DA055229-01 |
|
NIDA |
2022 |
|
|
Leveraging ΔFosB as a potential therapeutic for Alzheimers Disease |
| 3R01DA040621-07S1 |
|
NIDA |
2022 |
|
|
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity |
| 3R01DA046204-05S1 |
|
NIDA |
2022 |
|
|
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplement |
| 3R01DA052845-03S1 |
|
NIDA |
2022 |
|
|
Neuroepigenetic mechanisms of chronic low back pain using histone deacetylases PET imaging |
| 4R33DA048485-03 |
|
NIDA |
2022 |
|
|
Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes |
| 5R01DA039192-07 |
|
NIDA |
2022 |
